Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Market Cap	41.44B
Revenue (ttm)	6.98B
Net Income (ttm)	359.76M
Shares Out	n/a
EPS (ttm)	0.42
PE Ratio	115.18
Forward PE	36.55
Dividend	0.62 (2.14%)
Ex-Dividend Date	Jun 7, 2024

Volume	16,019,552
Average Volume	3,105,147
Open	27.20
Previous Close	26.95
Day's Range	26.60 - 30.80
52-Week Range	22.30 - 58.80
Beta	0.84
RSI	58.40
Earnings Date	Apr 28, 2025

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 10,185
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3347

Financial Performance

In 2024, HKG:3347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial numbers in CNY